Stratified AutoReminder: Better manage your patients. Reduce risk to your practice.

Stratified AutoReminderSM is a tool that randomly selects patients for urine drug monitoring based on pre-set parameters chosen by you. You can customize monitoring protocols for each patient based on your evaluation of that patient’s risk factors . This helps you:

  • Develop a systematic method of monitoring to reduce risk to you and your practice.
  • Streamline patient management with auto-generated lists of who to monitor.
  • Eliminate guesswork and potential bias in pain medication monitoring.
  • Align your treatment with guidelines and recommendations from professional organizations.

Eliminate Potential Bias in Urine Drug Testing

  • Monitoring the behavior alone of patients on chronic opioid treatment will fail to detect potential problems. In one study, 27% of patients with no behavioral issues had a positive urine drug screen for illicit or non-prescribed drugs.1
  • “Numerous peer-reviewed studies have determined that self-reports of illicit and non-prescribed controlled substances from pain patients are unreliable.”2

Learn more about Stratified AutoReminderSM. Fill out the form to the right

Align Your Treatment with what Professional Organizations Recommend

Stratified AutoReminder helps you treat patients in alignment with major clinical guidelines and recommendations, which recommend routine and random urine drug monitoring at  frequencies based on the patient’s risk.

  • Experts recommend that all patients on long-term opioid therapy should be tested because no patient is at zero risk for opioid abuse.3
  • Stratified AutoReminder reporting helps you assess patient risk on an ongoing basis. Experts recommend that “risk may be periodically reassessed, and should not be considered static.” 3

Urine Drug Monitoring Should be Periodic and Random

Urine Drug Monitoring Should be based on Risk Stratification

Published Expert Consensus Recommendations (2012)3

American Pain Society/American Academy of Pain Medicine Guidelines4

American Academy of Family Physicians5

American Society of Interventional Pain Physicians6

Department of Veterans Affairs/Department of Defense7


1- Katz N., Fanciullo GJ. Role of Urine Toxicology Testing in the Management of Chronic Opioid Therapy. Clin J Pain. 2002;18(4 suppl):S76-82. 2- Owen, G.T., Burton, A.W., Schade, C.M., Passik, S. (2012). Urine drug testing: Current recommendations and best practices. Pain Physician. 15(3S). 119-133. 3- Peppin J.F., Passik, S.D., Couto, J.E., Fine, P.G., Christo, P.J., Argoff, C … Goldfarb, N.I.. (2012) Recommendations for Urine Drug Monitoring as a Component of Opioid Therapy in the Treatment of Chronic Pain. Pain Medicine, 13 (7), 886-896. 4- Chou R., Fanciullo G.J., Fine, P.G., Adler, J.A., Ballantyne, J.C., Davies, P., Donovan, M. I. … Miaskowsi, C. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10(2), 113-130. 5- American Academy of Family Physicians. Pain Management and Opioid Abuse: A Public Health Concern. Position Paper. 2012. 6- Manchikanti, L., Abdi, S., Atluri, S., Balog, C.C., Benymain, R.M., Boswell, M.V., Brown, K.R. … Wargo, B.W. (2012) American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain: Part 2 – Guidance. Pain Physician. 15(3s). Retrieved from;%2015;S67-S116.pdf. 7- Department of Veterans Affairs, Department of Defense, The Management of Opioid Therapy for Chronic Pain Working Group, VA/DoD Clinical Practice Guideline, Management of Opioid Therapy for Chronic Pain, 2010, Washington, DC, [ .asp].